Improper OTC Loratadine Use Concerns Hinge On Delayed Physician Treatment
This article was originally published in The Tan Sheet
Executive Summary
Improper use of OTC Claritin for skin conditions other than chronic idiopathic urticaria would not cause direct harm but might lead to a delay in seeking appropriate medical treatment, FDA advisory committee members and Schering-Plough representatives said
You may also be interested in...
FDA Claritin Hypospadia Review Targeted For Summer Completion
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
FDA Claritin Hypospadia Review Targeted For Summer Completion
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months
FDA Claritin Hypospadia Review Targeted For Summer Completion
FDA's review of safety and birth registry data to determine whether Schering-Plough's Claritin (loratadine) could be linked to hypospadia is expected to take approximately three months